Navigation Links
Caliper Life Sciences to Webcast Investor Session of Open House
Date:6/8/2009

HOPKINTON, Mass., June 8 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. (Nasdaq: CALP) today announced that it will hold a Customer and Investor Open House entitled, "Innovation for Experimentation" to be held June 17, 2009 at Caliper's Hopkinton headquarters. The company will webcast the Investor Breakout Session from 2:30 - 4:00 p.m. EDT.

The investor portion of the conference will feature presentations by Kevin Hrusovsky, President and CEO, as well as several members of Caliper's executive team, who will outline Caliper's strategic priorities and the future direction of Caliper's technologies and services. The Customer Open House morning session will include presentations from over a dozen of the company's customers highlighting their innovative uses of Caliper's technologies in drug discovery and development and molecular biology.

Attendance at the event is by invitation only due to limited seating availability. Persons interested in reserving a seat should contact Cathy Portanova at cathy.portanova@caliperls.com. Interested parties may listen to a live broadcast of the Investor Breakout Session on the Caliper website at www.caliperLS.com in the Events section of the Investor Relations page. An audio archive of the webcast will be available in the Investors section of our website following the event.

About Caliper Life Sciences

Caliper Life Sciences is a premier provider of leading-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Cal
'/>"/>

SOURCE Caliper Life Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Caliper Life Sciences Reports First Quarter 2009 Results
2. Caliper Life Sciences Announces Date and Location of its 2009 Annual Meeting of Stockholders
3. EPA Presents Initial Results from Caliper Life Sciences ToxCast Screening Effort
4. Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results
5. Caliper Life Sciences Introduces Zephyr Genomics Workstation for Automated Liquid Handling
6. Caliper Life Sciences Announces Preliminary 2008 Fourth Quarter and Full Year Revenue Results
7. Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs
8. Caliper Enters Agreement to Divest Non-Core Pharmaceutical Development & Quality Analysis Product Line
9. Caliper Life Sciences Third Quarter 2008 Financial Results Conference Call Notice
10. Caliper Life Sciences and DiscoveRx Announce Availability of PathHunter eXpress Reagents for GPCR Assays
11. Caliper Life Sciences to Present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... SC (PRWEB) October 22, 2014 ... of its cardiovascular pharmacogenetics menu, which enables healthcare ... outcomes. With PCLS’s evidence-based results, healthcare providers ... and optimize their therapy, while minimizing risks for ... the U.S., according to the FDA [1] more ...
(Date:10/22/2014)... 2014   Synthetic Biologics, Inc. (NYSE MKT: ... serious infections and diseases, announced today that the U.S. ... Allowance for a composition of matter patent application that ... program, SYN-004. This is Synthetic Biologics, first allowed patent ... adds to the Company,s extensive C. difficile ...
(Date:10/22/2014)... , Oct. 22, 2014 Nuvilex, Inc. ... approximately 400 million people worldwide are living with diabetes, ... people by 2030.  The global market for diabetes treatments ... approximately 330,000 people worldwide died from pancreatic cancer.  Pancreatic ... due to cancer in the United States ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014 ... enterprise, announced today that rare disease expert John ... president, research. Dr. McKew brings more than two decades ... at the National Institutes of Health, Wyeth Research and ... McKew will lead aTyr,s efforts to expand and translate ...
Breaking Biology Technology:PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3
... WA, May 1 /PRNewswire-FirstCall/ - Oncothyreon Inc. ... filed an investigational new,drug (IND) application with ... a small molecule phosphatidylinositol-3-kinase (PI-3-kinase),inhibitor for the ... plans to initiate a Phase 1 clinical ...
... produced tiny liquid crystal devices with electrodes made from ... computer and TV displays based on this technology. , ... Dr Kostya Novoselov and colleagues from The School of ... report on the use of graphene as a transparent ...
... SAN DIEGO, April 30 Anadys Pharmaceuticals,Inc. (Nasdaq: ... improving,patient care by developing novel medicines in the ... financial results and highlights for the first,quarter ended ... in both of our development programs,during the first ...
Cached Biology Technology:Oncothyreon files investigational new drug application for PX-866 oncology compound 2Oncothyreon files investigational new drug application for PX-866 oncology compound 3Graphene-based gadgets may be just years away 2Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 2Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 3Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 4Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 5Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 6Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 7Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 8
(Date:10/17/2014)... is available in German . ... very few drugs. When treating overdoses, doctors are often limited ... difficult if there is a combination of drugs involved. So ... accidentally swallows his grandmother,s pills? ETH professor Jean-Christophe Leroux from ... find an answer to this question. "The task was to ...
(Date:10/16/2014)... are anything but sustainable: environmental damage to soil ... increasingly evident. Despite their disadvantages, however, monocultures remain ... the sole possibility of achieving higher yields in ... an ecology professor at the University of Zurich, ... forestry. After all, a new study carried out ...
(Date:10/15/2014)... assess the pandemic risk from strains of influenza virus ... allow ourselves to become complacent that the most substantial ... scientists. , Influenza pandemics arise when a new virus ... widespread immunity – spreads in the human population. There ... years, the worst of which – the 1918 Spanish ...
Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2
... Researchers at the Hebrew University of Jerusalem have discovered ... utilizing human embryonic stem cells. Their work paves the ... stem cell therapy. Human embryonic stem cells ... the mature human body (and are hence defined as ...
... people are alike." Yet when we consider the thousands of ... it is remarkable how much alike we are. ... but a general property of life. Biologists have long pondered ... great variation in genetics as well as environmental conditions. ...
... for Research Resources (NCRR), part of the National ... up to an estimated $122 million over the ... (IDeA) Networks of Biomedical Research Excellence (INBRE) in ... and sharing of research resources and expertise, these ...
Cached Biology News:Hebrew University researchers neutralize tumor growth in embryonic stem cell therapy 2Researchers find snippet of RNA that helps make individuals remarkably alike 2NIH grants $122 million in Institutional Development Awards 2NIH grants $122 million in Institutional Development Awards 3
Polypropylene test tube racks, used in Thermo Forma's line of Test Tube Rack holders...
For quantitative determination of Aldolase in Serum (an indicator of muscle damage). Ready-to-use liquid stable reagent. Formulated to eliminate interference from pyruvates. Application sheets are ...
This Universal 24" X 18" (61 X 45.7cm.) shaker platforms will accept any Thermo Forma shaker flask clip....
...
Biology Products: